Structure of Nystatin
CAS No.: 1400-61-9
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Nystatin is a polyene antifungal drug used to treat fungal infections of the mouth, skin, vagina, and intestinal tract.
Synonyms: Fungicidin
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 1400-61-9 |
Formula : | C47H75NO17 |
M.W : | 926.09 |
SMILES Code : | C[C@@H]1OC(C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@@](O)(O[C@H]2C[C@H](/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@@H]([C@@H](O)[C@H]1C)C)O[C@H]3[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O3)C[C@H](O)[C@H]2C(O)=O)=O |
Synonyms : |
Fungicidin
|
MDL No. : | MFCD00036240 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
Concentration | Treated Time | Description | References |
C. lipolytica | 0.125–16 µg/ml | 24 and 48 hours | To evaluate the in vitro activity of nystatin and liposomal nystatin against C. lipolytica, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. | J Clin Microbiol. 2002 Apr;40(4):1406-12. |
C. lusitaniae | 0.125–16 µg/ml | 24 and 48 hours | To evaluate the in vitro activity of nystatin and liposomal nystatin against C. lusitaniae, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. | J Clin Microbiol. 2002 Apr;40(4):1406-12. |
C. krusei | 0.125–16 µg/ml | 24 and 48 hours | To evaluate the in vitro activity of nystatin and liposomal nystatin against C. krusei, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. | J Clin Microbiol. 2002 Apr;40(4):1406-12. |
C. parapsilosis | 0.125–16 µg/ml | 24 and 48 hours | To evaluate the in vitro activity of nystatin and liposomal nystatin against C. parapsilosis, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. | J Clin Microbiol. 2002 Apr;40(4):1406-12. |
C. tropicalis | 0.125–16 µg/ml | 24 and 48 hours | To evaluate the in vitro activity of nystatin and liposomal nystatin against C. tropicalis, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. | J Clin Microbiol. 2002 Apr;40(4):1406-12. |
C. glabrata | 0.125–16 µg/ml | 24 and 48 hours | To evaluate the in vitro activity of nystatin and liposomal nystatin against C. glabrata, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. | J Clin Microbiol. 2002 Apr;40(4):1406-12. |
C. albicans | 0.125–16 µg/ml | 24 and 48 hours | To evaluate the in vitro activity of nystatin and liposomal nystatin against C. albicans, results showed that nystatin and liposomal nystatin exhibited good activity against all tested Candida species. | J Clin Microbiol. 2002 Apr;40(4):1406-12. |
HEK-293 cells | 3.9 to 125 µg/mL | 24 hours | To evaluate the cytotoxicity of Nystatin nanocomposites on HEK-293 cells. Results showed that nanocomposites inhibited only 12% growth of HEK-293 cells at 125 µg/mL, indicating low cytotoxicity. | Molecules. 2023 Feb 15;28(4):1836. |
Candida dubliniensis CD36 | 3.52 mg/L (MIC) | 24 hours | Evaluation of the minimum inhibitory concentration (MIC) of Nystatin against Candida dubliniensis CD36, showing an MIC of 3.52 mg/L. | essential oil inhibits virulence patterns of Candida spp. and potentiates the effects of fluconazole and nystatin in vitro. |
Candida krusei ATCC 6258 | 1.40 mg/L (MIC) | 24 hours | Evaluation of the minimum inhibitory concentration (MIC) of Nystatin against Candida krusei ATCC 6258, showing an MIC of 1.40 mg/L. | essential oil inhibits virulence patterns of Candida spp. and potentiates the effects of fluconazole and nystatin in vitro. |
Candida albicans ATCC 10231 | 0.48 mg/L (MIC) | 24 hours | Evaluation of the minimum inhibitory concentration (MIC) of Nystatin against Candida albicans ATCC 10231, showing an MIC of 0.48 mg/L. | essential oil inhibits virulence patterns of Candida spp. and potentiates the effects of fluconazole and nystatin in vitro. |
Candida albicans ATCC 90029 | 0.33 mg/L (MIC) | 24 hours | Evaluation of the minimum inhibitory concentration (MIC) of Nystatin against Candida albicans ATCC 90029, showing an MIC of 0.33 mg/L. | essential oil inhibits virulence patterns of Candida spp. and potentiates the effects of fluconazole and nystatin in vitro. |
Pichia kudriavzevii | 8-64 µg/ml | 24-48 hours | To evaluate the Minimum Inhibitory Concentration (MIC) and Minimum Fungicidal Concentration (MFC) of Nystatin against P. kudriavzevii. Results showed that 61.9% of isolates had dose-dependent sensitivity to Nystatin, while 28.57% were resistant. | BMC Microbiol. 2024 Sep 10;24(1):333. |
Candida albicans SC5314 | 0.25–1 µM | 3 days | Inhibition of filamentation in C. albicans, with enhanced efficacy when combined with 4-AQ derivatives | NPJ Biofilms Microbiomes. 2024 Dec 13;10(1):146. |
Candida dubliniensis 40/01 | 0.0156–16 µg/ml | 48 hours | To evaluate the effect of OligoG in combination with nystatin on the minimum inhibitory concentration (MIC) of Candida dubliniensis. Results showed a 32-fold reduction in MIC value when nystatin was used in combination with 6% OligoG. | Front Cell Infect Microbiol. 2023 Jan 31;13:1122340. |
Candida auris NCPF 8971 | 0.0156–16 µg/ml | 48 hours | To evaluate the effect of OligoG in combination with nystatin on the minimum inhibitory concentration (MIC) of Candida auris. Results showed a 2-fold reduction in MIC value when nystatin was used in combination with 6% OligoG. | Front Cell Infect Microbiol. 2023 Jan 31;13:1122340. |
Candida parapsilosis W23 | 0.0156–16 µg/ml | 48 hours | To evaluate the effect of OligoG in combination with nystatin on the minimum inhibitory concentration (MIC) of Candida parapsilosis. Results showed a 4-fold reduction in MIC value when nystatin was used in combination with 6% OligoG. | Front Cell Infect Microbiol. 2023 Jan 31;13:1122340. |
Candida albicans ATCC 90028 | 0.0156–16 µg/ml | 48 hours | To evaluate the effect of OligoG in combination with nystatin on the minimum inhibitory concentration (MIC) of Candida albicans. Results showed a 4-fold reduction in MIC value when nystatin was used in combination with 6% OligoG. | Front Cell Infect Microbiol. 2023 Jan 31;13:1122340. |
Candida albicans | 3.9 to 500 µg/mL | 48 hours | To evaluate the inhibitory effect of Nystatin nanocomposites on the growth of Candida albicans. Results showed that nanocomposites significantly inhibited the growth of C. albicans at a concentration of 3.9 µg/mL. | Molecules. 2023 Feb 15;28(4):1836. |
C. albicans ATCC 26278 | 100 μg/mL | Overnight | To determine the minimum inhibitory concentration of Nystatin-PLP adduct, showing attenuated antifungal potency. | Mol Pharm. 2011 Feb 7;8(1):297-301. |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Zebrafish (Danio rerio) | Disseminated candidiasis model | 0.5–1 µM | Assessed after 24-hour treatment | Increased survival rate of infected embryos, with enhanced efficacy when combined with 4-AQ derivatives | NPJ Biofilms Microbiomes. 2024 Dec 13;10(1):146. | |
ICR female mice | Vulvovaginal candidiasis (VVC) model | Vaginal perfusion | 50.0 µL/dose | Administered on days 1, 6, and 16, with therapeutic effects monitored | Assess the therapeutic efficacy of ENNE against VVC, demonstrating significant reduction in vaginal fungal load and improved inflammatory response | Int J Nanomedicine. 2020 Mar 25;15:2027-2044 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT00659971 | Oral Candidiasis | Phase 2 | Completed | - | United States, North Carolina ... More >> Rosedale Infectious Disease Huntersville, North Carolina, United States, 28078 Less << |
NCT01111942 | Head and Neck Cancer | Early Phase 1 | Terminated(lack of enrollment) | - | United States, Illinois ... More >> Southern Illinois University School of Medicine Springfield, Illinois, United States, 62701 Less << |
NCT00814359 | Head and Neck Cancer ... More >> Mucositis Less << | Phase 3 | Completed | - | Canada, Ontario ... More >> Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Less << |
NCT01886001 | Colonization | Not Applicable | Completed | - | United States, Virginia ... More >> Univeristy of Virginia Health System Charlottesville, Virginia, United States, 22908 Less << |
NCT01893060 | Line Insertion Site ... More >> Central Line-associated Bloodstream Infection (CLABSI) Less << | Not Applicable | Unknown | July 2014 | United States, Virginia ... More >> University of Virginia HealthSystem Recruiting Charlottesville, Virginia, United States, 22932 Contact: David A Kaufman, MD 434-924-5428 dak4r@virginia.edu Contact: Amy E. Blackman, MD 434-982-0263 as5v@virginia.edu Less << |
NCT00078559 | - | Completed | - | - | |
NCT03320460 | Lichen Planus, Oral ... More >> Low-Level Light Therapy Less << | Not Applicable | Not yet recruiting | December 2020 | - |
NCT02409147 | Uterus Transplant | Not Applicable | Suspended(Lack of funding) | January 2025 | United States, Nebraska ... More >> University of Nebraska Medical Center Omaha, Nebraska, United States, 68198 Less << |
NCT03399331 | Oral Mucositis ... More >> Leukemia Less << | Phase 1 | Recruiting | July 1, 2021 | Lebanon ... More >> American Univeristy of Beirut Medical Center Recruiting Beirut, Lebanon Contact: lina K Badr, PhD 01196132815041 lb24@aub.edu Sub-Investigator: Rima Saad, MSN Sub-Investigator: Rebecca El Asmar, MSN Less << |
NCT00078559 | Kidney Transplantation ... More >> Kidney Disease Less << | Phase 1 Phase 2 | Completed | - | United States, Wisconsin ... More >> University of Wisconsin - Department of Medicine Madison, Wisconsin, United States, 53792-1735 Less << |
NCT00634166 | Burns | Phase 4 | Terminated(FDA request as stud... More >>y could not serve as the confirmatory trial as required under Subpart H approval.) Less << | - | United States, Alabama ... More >> University of South Alabama Medical Center Mobile, Alabama, United States, 36617 United States, California Arrowhead Regional Medical Center Redlands, California, United States, 92373 United States, Florida Shands Burn Center - Univ. of Florida Gainesville, Florida, United States, 32610 United States, Illinois Loyola University Medical Center Maywood, Illinois, United States, 60153 The Plastic Surgery Institute - Southern Illinois Univ. School of Medicine Springfield, Illinois, United States, 62794-9653 United States, Kansas University of Kansas Medical Center Kansas City, Kansas, United States, 66160 United States, Maryland John's Hopkins Burn Center Baltimore, Maryland, United States, 21224 United States, Missouri University of Missouri Healthcare - Dept. of Surgery Columbia, Missouri, United States, 65212 United States, North Carolina Wake Forest University - Department of General Surgery Winston-Salem, North Carolina, United States, 27157 Less << |
NCT02142543 | Minor Recurrent Aphthous Stoma... More >>titis Lesions Less << | Early Phase 1 | Completed | - | United States, Texas ... More >> Texas A&M Baylor College of Dentisry Dallas, Texas, United States, 75246 Less << |
NCT02208154 | ICU-ecology (Multidrug Resista... More >>nt Bacteria) ICU-acquired Bacteraemia Less << | Phase 3 | Completed | - | Belgium ... More >> Universitair Ziekenhuis Antwerpen Edegem, Belgium, B-2650 Algemeen Ziekenhuis Sint Lucas Gent, Belgium, 9000 Universitair Ziekenhuis Gent Gent, Belgium, 9000 CHU Liege Liege, Belgium, 4000 Clinique Saint-Pierre Ottignies Ottignies, Belgium, 340 Italy Ospedale San Camillo Rome, Italy, 00152 Portugal Hospital Geral de Santo António (Centro Hospitalar do Porto, EPE) Porto, Portugal, 4099-001 Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE Vila Real, Portugal, 5000 - 508 Slovenia University clinic of respiratory and allergic diseases Golnik, Slovenia, 4204 Spain Hospital Clinic of Barcelona Barcelona, Spain, 08036 l'Hospital de la Santa Creu i Sant Pau Barcelona, Spain, 08041 Hospital Universitario y Politécnico La Fé de Valencia Valencia, Spain, 46026 United Kingdom University Hospital of Wales Cardiff, United Kingdom, CF14 4XW Less << |
NCT00674999 | Burn | Phase 2 Phase 3 | Withdrawn(Hurricane- terminate... More >>d study due to skin bank being destroyed) Less << | - | - |
NCT01699412 | Graft vs Host Disease ... More >> Oral Manifestations Less << | Phase 3 | Completed | - | Brazil ... More >> Hematology and Hemotherapy Center Campinas, São Paulo, Brazil, 13083-878 Clementino Fraga Filho University Hospital Rio de Janeiro, Brazil, 21941-913 Less << |
NCT00634166 | - | Terminated(FDA request as stud... More >>y could not serve as the confirmatory trial as required under Subpart H approval.) Less << | - | - | |
NCT00942526 | Anastomotic Leakage | Phase 2 | Unknown | December 2010 | Taiwan ... More >> National Taiwan University Hospital Recruiting Taipei, Taiwan, 100 Contact: Pei-Ming Huang, MD +886-2-23123456 ext 63509 e370089@gmail.com Principal Investigator: Pei-Ming Huang, MD Less << |
NCT02515656 | Vaginitis | Phase 3 | Completed | - | Czech Republic ... More >> TURKOVA Praha, Czech Republic France PERCEVAL Lyon, France, 69009 Serbia MARICIC Belgrade, Serbia Slovakia GATOVA Martin, Slovakia Less << |
NCT02389036 | Critical Illness ... More >> Sepsis Septic Shock Ventilator Associated Pneumonia Less << | Phase 3 | Recruiting | December 2020 | Australia, New South Wales ... More >> The George Institute for Global Health Recruiting Sydney, New South Wales, Australia, 2000 Contact: John Myburgh, | MBBCh PhD 61 2 8052 4348 jmyburgh@georgeinstitute.org.au Less << |
NCT02444481 | Vaginitis | Phase 4 | Completed | - | - |
NCT01743690 | Oral Lichen Planus ... More >> Candida Infection Less << | Not Applicable | Completed | - | Denmark ... More >> University of Copenhagen Copenhagen, Denmark, 2100 Less << |
NCT00845819 | Oral Mucositis | Phase 2 | Completed | - | Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Republic of, 110-744 Less << |
NCT00629122 | Kidney Failure, Chronic | Phase 4 | Completed | - | United States, New York ... More >> NewYork-Presbyterian Hospital New York, New York, United States, 10065 Less << |
NCT00629122 | - | Completed | - | - | |
NCT02662374 | Oral Mucositis | Phase 4 | Unknown | May 2016 | - |
NCT00002742 | Chronic Myeloproliferative Dis... More >>orders Infection Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Less << | Phase 3 | Completed | - | - |
NCT01411748 | Anticandidal Property of Sacch... More >>aromyces Boulardii on Very Low Birth Weight Infants Less << | Phase 4 | Unknown | December 2011 | Turkey ... More >> Zekai Tahir Burak Maternity Teaching Hospital, Division of Neonatology Recruiting Ankara, Turkey, 06230 Contact: Gamze Demirel, MD +905324540156 kgamze@hotmail.com Principal Investigator: Gamze Demirel, MD Less << |
NCT00250133 | - | Terminated(Unable to obtain fu... More >>nding to complete study never started study) Less << | - | United States, Pennsylvania ... More >> University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States, 15213 Less << | |
NCT02166450 | Denture Stomatitis | UNKNOWN | - | Zbigniew ?ak Voivodeship Denta... More >>l Clinic, Krakow, 31-135, Poland|Jagiellonian University Dental Clinic, Krakow, 31-155, Poland Less << | |
NCT03237533 | Oral Lichen Planus | Early Phase 1 | Recruiting | December 31, 2017 | Pakistan ... More >> The university of Faisalabad Recruiting Faisalābād, Punjab, Pakistan, 38000 Contact: Sadaf Rashid, BDS +923237791689 durr_e_sadaf@hotmail.com Contact: Arsalan Wahid, M. Phil +923216685228 dr.arsalanmalik@gmail.com Less << |
NCT00128323 | Candidiasis, Oral | Phase 3 | Completed | - | Malawi ... More >> Queen Elizabeth Central Hospital, Paediatric Dept, Box 360 Blantyre, Malawi, 3 Less << |
NCT01798537 | Bacteremia Associated With Int... More >>ravascular Line Ventilator Associated Pneumonia Bacteremia Less << | Phase 2 Phase 3 | Unknown | July 2015 | Israel ... More >> Rambam Health Care Campus Not yet recruiting Haifa, Israel, 31096 Contact: Yaron P Bar-Lavie, M.D. ++972-50-206-2027 y_barlavie@rambam.health.gov.il Contact: Mical Paul, Prof. ++972-50-206-2140 m_paul@rambam.health.gov.il Principal Investigator: Yaron P Bar-Lavie, M.D. Principal Investigator: Mical Paul, Prof. Less << |
NCT01867164 | - | Completed | - | - | |
NCT00002112 | Candidiasis, Oral ... More >> HIV Infections Less << | Not Applicable | Completed | - | United States, California ... More >> California Med Research Group Fresno, California, United States, 93726 UCSF Hosp San Francisco, California, United States, 94143 United States, Maryland Johns Hopkins School of Medicine Baltimore, Maryland, United States, 21205 United States, Pennsylvania Med College of Pennsylvania Philadelphia, Pennsylvania, United States, 19129 United States, Virginia Hampton Roads Med Specialists Hampton, Virginia, United States, 23666 Less << |
NCT01867164 | Vaginitis Inf... More >>ectious Vaginosis Less << | Phase 3 | Completed | - | Mexico ... More >> DF, Mexico Mexico D.F., Mexico Less << |
NCT01718912 | Periodontal Disease | Not Applicable | Completed | - | Canada, Ontario ... More >> Toronto Rehabilitation Institute, Dental Department Toronto, Ontario, Canada, M5G 2A2 Less << |
NCT00001812 | Candidiasis, Oral|Gastrointest... More >>inal Diseases|Stomatitis Less << | PHASE3 | COMPLETED | 2000-08-01 | National Cancer Institute (NCI... More >>), Bethesda, Maryland, 20892, United States Less << |
NCT01531192 | Very Low Birth Weight Infants | Phase 4 | Completed | - | Turkey ... More >> Zekai Tahir Burak Maternity Teaching Hospital, Division of Neonatology Ankara, Turkey, 06110 Less << |
NCT00002293 | Candidiasis, Oral|HIV Infectio... More >>ns Less << | COMPLETED | - | Birmingham Veterans Administra... More >>tion Med Ctr / Univ of Alabama, Birmingham, Alabama, 35233, United States|Bristol - Myers Squibb Co, Princeton, New Jersey, 085434000, United States Less << | |
NCT00002057 | Candidiasis, Oral|HIV Infectio... More >>ns Less << | COMPLETED | - | Birmingham Veterans Administra... More >>tion Med Ctr / Univ of Alabama, Birmingham, Alabama, 35233, United States|Bristol - Myers Squibb Co, Princeton, New Jersey, 085434000, United States Less << | |
NCT00001998 | HIV Infections | COMPLETED | - | Twelve Oaks Hosp, Houston, Tex... More >>as, 77027, United States Less << | |
NCT00002313 | HIV Infections | Phase 1 | Completed | - | United States, Texas ... More >> Twelve Oaks Hosp Houston, Texas, United States, 77027 Less << |
NCT01198223 | Denture Stomatitis | Phase 2 | Completed | - | Iran, Islamic Republic of ... More >> QUMS Qazvin, Iran, Islamic Republic of Less << |
NCT02642900 | Photochemotherapy Reaction | Phase 4 | Completed | - | Brazil ... More >> Faculdade de Odontologia da Universidade de São Paulo São Paulo, Brazil, 05508-000 Less << |
NCT01427738 | - | Completed | - | - | |
NCT02186145 | Bacterial Vaginosis ... More >> Fungal Vaginal Infections Less << | Phase 3 | Unknown | January 2017 | Brazil ... More >> Faculty of Medicine of ABC (FMABC) Not yet recruiting Santo André, SP, Brazil, 09190-615 Contact: Marcus Vinícius Seroqui, Site Clinical Trials Manager +55 11 2829-5148 mv_seroqui@yahoo.com.br Principal Investigator: Emerson Oliveira, MD Less << |
NCT03390374 | Fungal Infections Systemic | Phase 4 | Completed | - | - |
NCT00002097 | HIV Infections | PHASE1 | COMPLETED | - | Twelve Oaks Hosp, Houston, Tex... More >>as, 77027, United States Less << |
NCT01495039 | Fungal Prophylaxis|Candida Inf... More >>ection|Critical Illness|Surgery Less << | PHASE4 | COMPLETED | 2025-02-10 | Intensive care Unit, Policlini... More >>co Hospital Bari, Bari, 70100, Italy Less << |
NCT01427738 | HIV-1 Infection | Phase 3 | Completed | - | Botswana ... More >> Gaborone Prevention/Treatment Trials CRS (12701) Gaborone, Botswana Molepolole Prevention/Treatment Trials CRS (12702) Molepolole, Botswana India BJ Medical College CRS (31441) Pune, Maharashtra, India, 411001 National AIDS Research Institute Pune CRS (11601) Pune, Maharashtra, India, 411026 Kenya AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601) Eldoret, Kenya, 30100 Walter Reed Project - Kenya Med. Research Institute Kericho CRS (12501) Kericho, Kenya, 20200 Malawi College of Med. JHU CRS (30301) Blantyre, Malawi South Africa Durban Adult HIV CRS (11201) Durban, South Africa, 4013 SF Uganda Joint Clinical Research Centre (JCRC) (12401) Kampala, Uganda Zimbabwe UZ-Parirenyatwa CRS (30313) Harare, Zimbabwe Less << |
NCT04550546 | Dental Caries | PHASE1 | COMPLETED | 2022-02-28 | Eastman Dental Institute, Roch... More >>ester, New York, 14642, United States Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.08mL 0.22mL 0.11mL |
5.40mL 1.08mL 0.54mL |
10.80mL 2.16mL 1.08mL |